PMID- 32364064
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20211204
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 28
IP  - 8
DP  - 2021
TI  - Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of 
      Inflammatory Bowel Diseases.
PG  - 1605-1624
LID - 10.2174/0929867327666200504081503 [doi]
AB  - Inflammatory bowel disease (IBD) is a general term for a group of chronic and 
      progressive disorders. Several cellular and biomolecular pathways are implicated 
      in the pathogenesis of IBD, yet the etiology is unclear. Activation of the 
      mammalian target of rapamycin (mTOR) pathway in the intestinal epithelial cells 
      was also shown to induce inflammation. This review focuses on the inhibition of 
      the mTOR signaling pathway and its potential application in treating IBD. We also 
      provide an overview of plant-derived compounds that are beneficial for the IBD 
      management through modulation of the mTOR pathway. Data were extracted from 
      clinical, in vitro and in vivo studies published in English between 1995 and May 
      2019, which were collected from PubMed, Google Scholar, Scopus and Cochrane 
      library databases. Results of various studies implied that inhibition of the mTOR 
      signaling pathway downregulates the inflammatory processes and cytokines involved 
      in IBD. In this context, a number of natural products might reverse the 
      pathological features of the disease. Furthermore, mTOR provides a novel drug 
      target for IBD. Comprehensive clinical studies are required to confirm the 
      efficacy of mTOR inhibitors in treating IBD.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Lashgari, Naser-Aldin
AU  - Lashgari NA
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
FAU - Roudsari, Nazanin Momeni
AU  - Roudsari NM
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
FAU - Momtaz, Saeideh
AU  - Momtaz S
AD  - Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, 
      Iran.
FAU - Ghanaatian, Negar
AU  - Ghanaatian N
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
FAU - Kohansal, Parichehr
AU  - Kohansal P
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
FAU - Farzaei, Mohammad Hosein
AU  - Farzaei MH
AD  - Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University 
      of Medical Sciences, Kermanshah, Iran.
FAU - Afshari, Khashayar
AU  - Afshari K
AD  - Experimental Medicine Research Center, Department of pharmacology, School of 
      Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Halal Research Center of IRI, FDA, Tehran, Iran.
FAU - Abdolghaffari, Amir Hossein
AU  - Abdolghaffari AH
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Colitis
MH  - Humans
MH  - Inflammation
MH  - *Inflammatory Bowel Diseases/drug therapy
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases
OTO - NOTNLM
OT  - Gastroenterology
OT  - crohn's disease
OT  - inflammatory bowel disease
OT  - mammalian target of rapamycin
OT  - natural products
OT  - ulcerative colitis
EDAT- 2020/05/05 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/05/05 06:00
PHST- 2019/11/24 00:00 [received]
PHST- 2020/03/24 00:00 [revised]
PHST- 2020/03/29 00:00 [accepted]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - CMC-EPUB-106316 [pii]
AID - 10.2174/0929867327666200504081503 [doi]
PST - ppublish
SO  - Curr Med Chem. 2021;28(8):1605-1624. doi: 10.2174/0929867327666200504081503.